SPONSOR
Beijing Biotech
Total Trials
7
Recruiting
7
Phases
Phase 1, Phase 2, Phase 1
Conditions studied: Unresectable MelanomaMetastatic Cutaneous MelanomaMetastatic Uveal MelanomaCholangiocarcinomaIntrahepatic CholangiocarcinomaExtrahepatic CholangiocarcinomaGallbladder CarcinomaBiliary Tract CancerEpithelial Ovarian CancerPrimary Peritoneal Carcinoma
Beijing Biotech is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma, Cholangiocarcinoma.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beijing Biotech
How many clinical trials has Beijing Biotech sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Beijing Biotech, of which 7 are actively recruiting participants. These trials cover conditions including Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beijing Biotech research focus on?
Beijing Biotech clinical trials span Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma, Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beijing Biotech clinical trial?
To participate in a Beijing Biotech trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beijing Biotech trials with current recruitment status updated daily.
Clinical Trials by Beijing Biotech
NCT07627698 Phase 1, Phase 2
Recruiting
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Unresectable Melanoma
NCT07641036 Phase 1, Phase 2
Recruiting
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Cholangiocarcinoma
NCT07480954 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Epithelial Ovarian Cancer
NCT07480941 Phase 1
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Glioblastoma
NCT07523542 Phase 1, Phase 2
Recruiting
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
NCT07551336 Phase 1
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Malignant Glioma
NCT07551349 Phase 1, Phase 2
Recruiting
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology